Cargando…
What every intensivist should know about Tocilizumab
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313874/ https://www.ncbi.nlm.nih.gov/pubmed/34315504 http://dx.doi.org/10.1186/s13054-021-03696-1 |
| _version_ | 1783729434368409600 |
|---|---|
| author | Hofmaenner, Daniel Andrea Wendel Garcia , Pedro David Ganter, Christoph Camille Brugger, Silvio D. Buehler, Philipp Karl David, Sascha |
| author_facet | Hofmaenner, Daniel Andrea Wendel Garcia , Pedro David Ganter, Christoph Camille Brugger, Silvio D. Buehler, Philipp Karl David, Sascha |
| author_sort | Hofmaenner, Daniel Andrea |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8313874 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83138742021-07-27 What every intensivist should know about Tocilizumab Hofmaenner, Daniel Andrea Wendel Garcia , Pedro David Ganter, Christoph Camille Brugger, Silvio D. Buehler, Philipp Karl David, Sascha Crit Care Research Letter BioMed Central 2021-07-27 /pmc/articles/PMC8313874/ /pubmed/34315504 http://dx.doi.org/10.1186/s13054-021-03696-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Research Letter Hofmaenner, Daniel Andrea Wendel Garcia , Pedro David Ganter, Christoph Camille Brugger, Silvio D. Buehler, Philipp Karl David, Sascha What every intensivist should know about Tocilizumab |
| title | What every intensivist should know about Tocilizumab |
| title_full | What every intensivist should know about Tocilizumab |
| title_fullStr | What every intensivist should know about Tocilizumab |
| title_full_unstemmed | What every intensivist should know about Tocilizumab |
| title_short | What every intensivist should know about Tocilizumab |
| title_sort | what every intensivist should know about tocilizumab |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313874/ https://www.ncbi.nlm.nih.gov/pubmed/34315504 http://dx.doi.org/10.1186/s13054-021-03696-1 |
| work_keys_str_mv | AT hofmaennerdanielandrea whateveryintensivistshouldknowabouttocilizumab AT wendelgarciapedrodavid whateveryintensivistshouldknowabouttocilizumab AT ganterchristophcamille whateveryintensivistshouldknowabouttocilizumab AT bruggersilviod whateveryintensivistshouldknowabouttocilizumab AT buehlerphilippkarl whateveryintensivistshouldknowabouttocilizumab AT davidsascha whateveryintensivistshouldknowabouttocilizumab |